# A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

> **NCT05420545** · PHASE1 · UNKNOWN · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 36 (estimated)

## Conditions studied

- Metastatic Tumor
- Advanced Solid Tumor
- Renal Cell Carcinoma
- Ovarian Cancer
- Cervix Cancer

## Interventions

- **BIOLOGICAL:** CD70 CAR-T cells
- **BIOLOGICAL:** CD70 CAR-T cells

## Key facts

- **NCT ID:** NCT05420545
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-31
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05420545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05420545, "A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05420545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*